These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12071779)

  • 1. Automated signal generation in prescription-event monitoring.
    Heeley E; Wilton LV; Shakir SA
    Drug Saf; 2002; 25(6):423-32. PubMed ID: 12071779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach.
    Coulter DM
    Drug Saf; 2002; 25(6):433-9. PubMed ID: 12071780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription-event monitoring in Japan (J-PEM).
    Kubota K
    Drug Saf; 2002; 25(6):441-4. PubMed ID: 12071781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing studies: the work of the Drug Safety Research Unit.
    Mackay FJ
    Drug Saf; 1998 Nov; 19(5):343-53. PubMed ID: 9825948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
    Davies M; Wilton LV; Shakir SA
    Drug Saf; 2008; 31(4):313-23. PubMed ID: 18366242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription-event monitoring: developments in signal detection.
    Ferreira G
    Drug Saf; 2007; 30(7):639-41. PubMed ID: 17604421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database.
    Clark DW; Layton D; Wilton LV; Pearce GL; Shakir SA
    Drug Saf; 2001; 24(15):1143-54. PubMed ID: 11772147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.
    Key C; Layton D; Shakir SA
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):143-8. PubMed ID: 11998539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.
    Evans SJ; Waller PC; Davis S
    Pharmacoepidemiol Drug Saf; 2001; 10(6):483-6. PubMed ID: 11828828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescriber profile and post-marketing surveillance.
    Inman W; Pearce G
    Lancet; 1993 Sep; 342(8872):658-61. PubMed ID: 8103150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel statistical tools for monitoring the safety of marketed drugs.
    Almenoff JS; Pattishall EN; Gibbs TG; DuMouchel W; Evans SJ; Yuen N
    Clin Pharmacol Ther; 2007 Aug; 82(2):157-66. PubMed ID: 17538548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative methods in pharmacovigilance: focus on signal detection.
    Hauben M; Zhou X
    Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.